Summary of the Conference Call for Juzi Biotechnology Company Overview - **Company**: Juzi Biotechnology - **Key Brands**: Kefu Mei and Keli Jin Industry Insights - **Market Trends**: The recombinant collagen market continues to show strong growth potential, with no signs of slowing down. The demand for products in this category remains robust, as evidenced by the high growth rates of key products and positive feedback from new product launches [4][10]. Core Points and Arguments - **Product Innovation**: Juzi Biotechnology is driving growth through product iterations, such as the upgrade of collagen peptide to version 2.0, and the introduction of new products like Focus Cream and Honey Repair Cream. These new products have received positive feedback from distribution channels and are expected to become new growth drivers [2][5]. - **Kefu Mei Brand Strengths**: Kefu Mei focuses on efficacy and safety, having established professional trust through medical device certification. The brand is expanding its product line into niche areas such as acne treatment and thermal injury repair, while also enhancing offline direct store presence to improve market performance [2][9]. - **Sales Performance**: Kefu Mei's collagen stick accounts for approximately 30% of total sales and continues to grow rapidly. The new customer acquisition rate is close to 50%, with a repurchase rate significantly higher than the industry average [2][12]. - **Keli Jin Brand Dynamics**: Keli Jin has achieved short-term growth through organizational restructuring and product line optimization. However, long-term growth may face challenges due to potential limitations in collagen technology for anti-aging effects [2][20]. - **Regulatory Challenges**: Sales of Class II medical device products are growing steadily, but the approval process for Class III medical devices is slow, with uncertain timelines for specific approvals despite receiving priority review qualifications for collagen fillers [2][21]. Financial Performance - **Revenue Growth**: Juzi Biotechnology has experienced rapid revenue and profit growth, although the sales expense ratio has increased. The company plans to control this ratio through product combination sales and customer referral strategies [6][7]. Marketing and Competitive Landscape - **Competitive Positioning**: Kefu Mei differentiates itself from competitors by emphasizing safety and efficacy. The brand has established a strong medical aesthetic image through partnerships with hospitals and medical institutions, contrasting with competitors that rely on celebrity endorsements [17][25]. - **Market Competition**: While other brands have launched collagen products, Kefu Mei's unique positioning and established trust in safety and efficacy mitigate significant competitive threats. The market is expanding collectively rather than through direct competition [25]. Product Strategy - **Product Development**: Kefu Mei's strategy includes launching successful single products and then expanding related skincare offerings. The brand also targets various consumer needs with different product forms [11][12]. - **New Product Launches**: The Focus Cream and Zhenyu Secret Repair Cream have distinct market positions, with the latter targeting a high-end consumer segment and addressing specific skin repair needs [18]. Future Outlook - **Growth Projections**: Kefu Mei is expected to achieve a growth rate of 40% to 50% in Q1 2025, with an annual performance forecast of 25% to 28%. The overall performance is anticipated to remain stable due to new product launches and marketing strategies [10][19]. Additional Considerations - **Consumer Sentiment**: Recent controversies regarding product ingredient content are not expected to significantly impact the company's fundamentals, as consumer recognition of product efficacy remains high [3][24]. - **Offline Expansion**: Kefu Mei has begun establishing offline direct stores, with plans to open 40 new locations in 2025. This strategy aims to enhance member interaction and improve market performance [22][23].

【文/王力 编辑/周远方】 5月，国内医美行业接连陷入舆论风暴。先是华熙生物（688363.SH）公开炮轰券商研究报告"贬低玻尿酸、炒作重组胶原蛋白"，矛头直指竞争对手巨子生 物；随后，网红博主"大嘴博士"郝宇发布检测报告，质疑巨子生物(02367.HK)旗下明星产品"胶原棒"存在成分虚标、核心氨基酸缺失等问题。 上海某高校生物结构学博士刘东（化名）向观察者网表示，该事件能直观反应出护肤品行业的检测乱象，刘博士表示："巨子生物采用的国标检测方法在专 业领域来看是滞后的，依托《中国药典》2020年版通则0731蛋白质测定法，其六类检测手段在化妆品领域近乎集体失效——其中，凯氏定氮法通过总氮量推 算蛋白质，这正是三鹿奶粉三聚氰胺事件中暴雷的'古董方法'。" 刘博士进一步表示，"凯氏定氮法化妆品中任意含氮物质都能虚增蛋白数据，而0731其他方法或因胶原蛋白特性失效，或对复杂成分抗干扰性极差。反观博 主采用的检测手段虽存在局限性，但只要实验条件规范、数据真实，准确度以及可信度远大于所述国家标准。" at 22 21 . u 上感露'E 日葡萄酒店里" add-1880001 - lley 文 可复美胶原棒图片来自社交 ...

Core Viewpoint - The controversy surrounding the skincare brand Kefu Mei, owned by Juzhi Biotechnology, has raised significant concerns about the authenticity of its flagship product, the recombinant collagen essence, which was alleged to contain only 0.0177% collagen, contradicting regulatory standards that require non-trace ingredients to exceed 0.1% [1][2][3] Company Summary - Juzhi Biotechnology, established in 2000, is a leading player in the recombinant collagen market in China, with a revenue growth from 900 million yuan in 2019 to 5.5 billion yuan in 2024, marking a more than fivefold increase [8] - The company reported a revenue of 5.539 billion yuan in 2024, a year-on-year increase of 57.2%, and a net profit of 2.062 billion yuan, up 42.1% [8] - Kefu Mei, the core brand of Juzhi Biotechnology, generated 4.54 billion yuan in revenue in 2024, reflecting a significant growth of 62.9% [9] Industry Summary - The recombinant collagen market in China was valued at 10.8 billion yuan in 2021 and is projected to surge to 219.38 billion yuan by 2030, with a compound annual growth rate of 44.93% [8] - The absence of industry standards for the collagen content in cosmetics has led to regulatory ambiguities, as highlighted by the ongoing controversy [7] - The recent scrutiny of Juzhi Biotechnology's products comes at a time when recombinant collagen is gaining popularity in the cosmetic industry, potentially replacing hyaluronic acid as a preferred ingredient [9]

Core Viewpoint - The controversy surrounding Juzhibio's flagship product, the "Recombinant Collagen Essence," has raised significant concerns about its actual collagen content and potential false advertising, leading to a sharp decline in its stock price and questioning the company's marketing practices [1][3]. Group 1: Product Controversy - A report by the self-media "Big Mouth Doctor" claims that the actual recombinant collagen content in Juzhibio's "Recombinant Collagen Essence" is only 0.0177%, which is below the cosmetic labeling standard of 0.1% [2][3]. - The report also highlights the absence of glycine, a key structural component of collagen, challenging the product's technical authenticity [2]. - Juzhibio has denied these claims, asserting that internal tests show collagen content greater than 0.1% and questioning the validity of the testing methods used by the "Big Mouth Doctor" team [3]. Group 2: Financial Performance and Dependency - Juzhibio's revenue is heavily reliant on its skincare products, with 99.7% of revenue coming from this segment, while health products contribute only 0.3% [5]. - The "Recombinant Collagen" and "Keli Jin" brands account for over 90% of the company's revenue, indicating a significant dependency on these two brands [6][7]. - In 2024, Juzhibio's sales and distribution expenses are projected to be 2.008 billion yuan, while R&D expenses are only 106 million yuan, highlighting a 19-fold disparity [7]. Group 3: Market Impact - Following the allegations, Juzhibio's stock price fell by 8% after the market opened on May 26 [3]. - The affected product has been removed from all sales channels, including major platforms like Taobao, Douyin, and JD [3]. - If consumer backlash leads to collective lawsuits or mass returns, it could severely impact the company's sales performance during key promotional periods, jeopardizing its annual revenue growth targets [6].

Group 1: Consumer Trust and Brand Management - Consumer trust and preference are vital market resources for consumer-facing companies, reflecting their brand building and emergency strategies [1] - The integration of consumer brands with company operations has intensified, making public sentiment management crucial for brand reputation [1] - A quantitative scoring mechanism, the "Consumer Sentiment Warning Index," has been developed to evaluate companies' responses to public sentiment crises [1] Group 2: Company Case Study - Giant Biological - Giant Biological's core brand, Kefu Mei, is facing controversy over the collagen content in its products, following allegations of potential fraud by a beauty influencer [2][5] - The influencer's testing revealed a collagen content of only 0.0177%, raising questions about the product's integrity [2] - Giant Biological responded by asserting that their internal testing showed collagen levels exceeding 0.1%, but the lack of authoritative national standards for collagen testing has led to ongoing disputes [6][5] Group 3: Industry Implications - The controversy highlights the need for established industry standards regarding the safety and content of cosmetic ingredients, particularly recombinant collagen [6] - As a leading player in the industry, Giant Biological must address public concerns and enhance its long-term product quality monitoring systems [7] - The incident underscores the broader issue of ingredient safety and transparency in the rapidly evolving beauty sector [6] Group 4: Company Case Study - Perrier - Perrier, produced by Nestlé, is under investigation for consumer fraud related to water source contamination and improper treatment methods [7][8] - The investigation revealed that Perrier's production methods may not comply with European regulations for natural mineral water, raising significant health concerns [7] - Nestlé has reiterated its commitment to food safety and the integrity of its products, emphasizing collaboration with local stakeholders to protect water resources [10] Group 5: Market Impact and Brand Reputation - The scandal poses a severe threat to Perrier's brand image, which has been built on high-end positioning and quality [11] - Consumer trust in Perrier has been significantly undermined, prompting a reevaluation of their product choices [11] - To regain consumer confidence, Perrier must conduct thorough investigations, ensure transparency, and strengthen supply chain management [11]

Core Viewpoint - The controversy surrounding the alleged fraud of the collagen essence product from Giant Biological (02367.HK) continues to escalate, with significant focus on the testing methods used to validate the claims made by Dr. Hao Yu, who has accused the product of containing only 0.0177% of recombinant collagen [1][3][5]. Group 1: Allegations and Responses - Dr. Hao Yu claims that the key component "glycine" is missing from the collagen essence, raising doubts about the product's authenticity [3]. - Giant Biological has issued a statement denying the allegations, asserting that their internal testing shows collagen content greater than 0.1%, contradicting Dr. Hao's findings [5][6]. - The company emphasizes adherence to regulatory standards and claims that all products undergo rigorous quality control processes [6][8]. Group 2: Testing Methods - The testing methods used by Dr. Hao Yu have been questioned by Giant Biological, which argues that the methods are not recognized by industry standards and lack proper validation [1][10]. - Dr. Hao Yu defends his use of high-precision HPLC amino acid quantification method, stating it is widely accepted internationally and has been validated for accuracy [1][10]. - Giant Biological has committed to obtaining third-party testing results to further validate their claims, indicating that they are awaiting the results from multiple authoritative testing agencies [2][8]. Group 3: Industry Context - The lack of established industry standards for measuring recombinant collagen content in cosmetics has been highlighted as a significant issue in this controversy [10]. - Dr. Hao Yu's background in organic chemistry and experience in the cosmetics industry lend credibility to his claims, although he asserts that there is no competitive motive behind his allegations [11][14]. - The ongoing debate raises questions about product quality and consumer trust in the cosmetic industry, particularly regarding the accuracy of ingredient labeling [16].

Core Viewpoint - The controversy surrounding the collagen content in the "Kefumei" product from Giant Biological has raised significant questions about product labeling and industry standards, highlighting potential discrepancies between claimed and actual ingredient levels [4][6][9]. Group 1: Allegations and Findings - Dr. Hao Yu's report claims that the actual collagen content in the "Kefumei" collagen stick is only 0.0177%, significantly below the regulatory threshold of 0.1% [1][3]. - The report also indicates that key component glycine was not detected in the product, challenging the validity of Giant Biological's claims regarding their recombinant collagen technology [3][5]. - The detection method used by Dr. Hao Yu, which includes high-precision HPLC and calibration with 18 amino acid internal standards, is said to be highly sensitive and reliable [5]. Group 2: Company Response - In response to the allegations, Giant Biological emphasized the compliance of their products with regulatory standards and stated that their internal testing showed collagen content above 0.1% [6][8]. - The company criticized the detection methods used by Dr. Hao Yu as not being recognized by industry standards and claimed that the results lacked credibility due to methodological issues [6][7]. - Giant Biological announced that they have engaged multiple third-party testing agencies to verify their product's content and will disclose results once available [6][8]. Group 3: Industry Context - The incident has highlighted a broader issue within the recombinant collagen industry, where there is currently no unified testing method or standard, leading to significant discrepancies in reported results [9]. - The ongoing debate reflects a conflict between technical standards and commercial interests, impacting consumer trust and transparency in the medical aesthetics sector [9].

Core Viewpoint - The article discusses the controversy surrounding Giant Bio (巨子生物) and its flagship product, Kefu Mei (可复美), which has been accused of potential fraud regarding its collagen content, leading to a crisis of trust among investors and consumers [1][4]. Group 1: Controversy and Market Impact - On May 24, a report from "Dr. Yan's Research Institute" claimed that Kefu Mei's collagen content was undetectable, raising questions about the company's credibility and regulatory compliance [1][4]. - Following the allegations, Giant Bio's stock price fell over 10% on May 26, closing at 73.6 HKD per share, with a total market capitalization of 788.19 billion HKD [4]. - Other companies in the collagen market, such as Jinbo Bio (锦波生物), Marubi (丸美生物), and Furuida (福瑞达), also experienced stock price declines amid the controversy [4]. Group 2: Product and Testing Disputes - The report highlighted three main issues with Kefu Mei: the claimed collagen content was only 0.0177%, below the regulatory threshold of 0.1%, and the absence of glycine, a key amino acid in collagen [9][11]. - Giant Bio defended its product, stating that it complies with national standards and has undergone multiple testing phases to ensure quality [11]. - The lack of standardized testing methods for collagen products in China has been identified as a significant issue, leading to discrepancies in test results from different institutions [12]. Group 3: Industry Context and Growth Potential - The collagen market in China reached 192.4 billion CNY in 2022, with a projected compound annual growth rate of 44.93%, expected to reach 585.7 billion CNY by 2025 [20]. - Companies like Jinbo Bio and Marubi are actively developing their collagen products, with Jinbo Bio reporting a revenue increase of 84.92% in 2024 [20][21]. - The article emphasizes the need for a scientific testing framework and transparent regulatory oversight to address the ongoing challenges in the collagen industry [17][22].

Core Viewpoint - The controversy surrounding the collagen product "Human-Like Recombinant Collagen Essence" from Giant Bio is primarily focused on the alleged discrepancy between the claimed and actual content of recombinant collagen, with accusations of misleading advertising and lack of industry standards for testing [1][4][5]. Group 1: Allegations and Responses - A blogger claimed that the actual recombinant collagen content in the product is only 0.0177%, significantly lower than advertised [1][4]. - Giant Bio responded by stating that their internal tests show collagen content above 0.1%, disputing the blogger's claims and questioning the validity of the testing methods used [1][5][6]. - The blogger criticized Giant Bio for not addressing two key scientific questions in their response and emphasized the need for transparency and accountability [2]. Group 2: Testing Standards and Methodology - The lack of established industry and national standards for testing recombinant collagen in cosmetics has led to disputes over testing methods and ingredient definitions [3][6]. - The blogger used HPLC (High-Performance Liquid Chromatography) to detect amino acid content, finding only 0.0177%, which raises questions about the product's labeling [4][10]. - Industry experts noted that the testing methods used by both parties require proper validation to ensure reliability, and the methods referenced by Giant Bio may not be directly applicable to cosmetic regulations [6][7]. Group 3: Ingredient Definition and Labeling - The core issue also revolves around how recombinant collagen is defined and whether the product contains genuine collagen, as the absence of glycine in the test results raises doubts [8][11]. - The blogger argued that the product's labeling as "soluble collagen" may mislead consumers regarding its actual collagen content, similar to how other cosmetic ingredients can be misrepresented [7][11]. - Giant Bio claimed that their product meets labeling regulations, asserting that the soluble collagen content is above 0.1% and should be listed as a primary ingredient [6][9].

Core Viewpoint - The controversy surrounding Juzhibio's flagship product, Kefu Mei, has raised significant concerns about the authenticity of its collagen claims, leading to a crisis of trust among investors and consumers [1][3][6]. Company Summary - Juzhibio, known as a leader in recombinant collagen, has faced allegations of product falsification, particularly regarding its Kefu Mei product, which reportedly contains only 0.0177% collagen, below the regulatory threshold of 0.1% [3][4]. - The company has stated that all its products are compliant with regulatory standards and have undergone rigorous quality checks [4][6]. - Following the controversy, Juzhibio's stock price fell by 4.04% to HKD 73.6, with a total market capitalization of HKD 788.19 billion as of May 26 [2]. Industry Summary - The demand for aesthetic products, including hyaluronic acid and collagen, has been rising, with major players like Juzhibio and Jinbo Bio seeing growth despite market challenges [2][9]. - The recombinant collagen market in China is projected to grow significantly, reaching CNY 585.7 billion by 2025, with a compound annual growth rate of 44.93% [10][12]. - The lack of standardized testing methods for collagen products has led to discrepancies in product claims and consumer trust issues, highlighting the need for regulatory frameworks in the industry [5][8][12].